Posts

AstraZeneca seals near $1.8B renal disease pact with CSPC

on
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney (renal) diseases. Under the agreement, CSPC will receive a $30 million upfront payment and could earn up to approximately $1.74 billion in additional payments tied to development and sales-related milestones. AstraZeneca will have the option to obtain exclusive rights to develop, manufacture, and commercialize one preclinical small nucleic acid drug candidate globally, and a second candidate outside China; CSPC retains China rights to one of the assets. The collaboration focuses on siRNA candidates and leverages CSPC’s AI-powered siRNA discovery platform and targeted delivery technology for two renal disease targets; the specific diseases have not been disclosed. The deal was announced on July 2, 2026, and is part of AstraZeneca’s broader strategy to strengthen its cardiovascular, renal & metabolism pi...

PureTech Spins Off Celea with $180M Funding to Advance IPF Drug Deupirfenidone into Phase 3

on

The Francis Crick Institute and Medicines Discovery Catapult Open KQ Labs Applications, Accelerating the Next Wave of Data-Driven Health Innovation

on

New Nature Biotechnology Article Highlights the Need for Cell-Cell Interaction Data in AI Biology

on

Friday Five: Caris Life Sciences hits MCED market

on

Recent US moves add hurdles to US investments in China biotech

on

Production problems hamper Lantheus bid for FDA approval of LNTH-2501 radiopharma diagnostic kit

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

Zymeworks agrees to acquire Theravance Biopharma for $929 million in cash plus contingent consideration

on

Viridian's Lumvoa Gains FDA Nod for Thyroid Eye Disease, Setting Up Clash With Amgen's Tepezza

on

Ipsen acquires Kartos for $1.75B to add Jakafi combo therapy navtemadlin in myelofibrosis

on

BridgeBio achondroplasia pill shows compelling growth and body proportionality benefit

on

How one biotech is using 'digital twins' to study a muscle disease therapy

on